These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10169390)

  • 21. Interferons in the treatment of multiple myeloma.
    Cooper MR; Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Hjorth M
    Br J Haematol; 1997 Apr; 97(1):29-37. PubMed ID: 9136939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
    van Agthoven M; Segeren CM; Buijt I; Uyl-de Groot CA; van der Holt B; Lokhorst HM; Sonneveld P
    Eur J Cancer; 2004 May; 40(8):1159-69. PubMed ID: 15110879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
    Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
    Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha as maintenance therapy in patients with multiple myeloma.
    Schaar CG; Kluin-Nelemans HC; Te Marvelde C; le Cessie S; Breed WP; Fibbe WE; van Deijk WA; Fickers MM; Roozendaal KJ; Wijermans PW;
    Ann Oncol; 2005 Apr; 16(4):634-9. PubMed ID: 15741226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.
    Fritz E; Ludwig H
    Ann Oncol; 2000 Nov; 11(11):1427-36. PubMed ID: 11142483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.
    Corso A; Mangiacavalli S; Cocito F; Pascutto C; Ferretti VV; Pompa A; Ciampichini R; Pochintesta L; Mantovani LG
    PLoS One; 2013; 8(9):e75047. PubMed ID: 24098678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
    Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
    Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
    Palumbo A; Boccadoro M; Garino LA; Gallone G; Frieri R; Pileri A
    Eur J Haematol; 1992 Aug; 49(2):93-7. PubMed ID: 1397246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
    Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
    Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferons in the treatment of multiple myeloma.
    Cooper MR
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
    Zee B; Cole B; Li T; Browman G; James K; Johnston D; Sugano D; Pater J
    J Clin Oncol; 1998 Aug; 16(8):2834-9. PubMed ID: 9704736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
    N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.